What is acinar cell carcinoma of the pancreas?
Acinar cell carcinoma is an uncommon cancer of the pancreas. The pancreas has two main jobs. It makes digestive enzymes, which travel through ducts into the bowel, and it makes hormones such as insulin.
The enzyme-making cells are grouped in tiny clusters called acini. Acinar cell carcinoma develops from these cells, which is why it is different from the much more common pancreatic ductal adenocarcinoma.
Acinar cell carcinoma accounts for only a small fraction of pancreatic tumours, estimated at between 0.2% and about 4% depending on the series (Ikezawa et al., 2024). It affects men more often than women, usually in their 50s to 70s, but it can also occur in children.
These tumours are often large when found, with a typical size of around 5 cm, and they frequently sit in the head of the pancreas (Ikezawa et al., 2024). Some produce so much of the enzyme lipase that it leaks into the blood. This can cause painful fatty lumps under the skin and joint pain, a rare but striking pattern.
Compared with ductal adenocarcinoma, acinar cell carcinoma usually has a better outlook. Surgery is the main treatment when the cancer has not spread, but it often comes back afterwards. For advanced disease, chemotherapy is used, and many tumours carry gene changes such as BRCA1, BRCA2 or ATM, which can make platinum drugs and PARP inhibitors particularly useful.
1. Key facts at a glance
| Feature | Details |
|---|---|
| Type of cancer | Carcinoma arising from the enzyme-producing (acinar) cells of the pancreas |
| How common | Rare; roughly 1-2% of adult pancreatic tumours |
| Typical age | Usually 50-70; occasionally children and teenagers |
| Sex | More common in men |
| Typical size at diagnosis | Around 5 cm |
| Usual site | Head of the pancreas more often than body or tail |
| Blood test clue | Raised lipase in a quarter to more than half of patients |
| Main treatment | Surgery if localised; chemotherapy such as FOLFIRINOX if advanced |
| Outlook | Better than ductal adenocarcinoma; recurrence is common |
2. Types of acinar cell carcinoma
| Type | Description |
|---|---|
| Pure acinar cell carcinoma | The usual form; cells show only acinar features |
| Acinar cell cystadenocarcinoma | A rare form with large cystic spaces |
| Mixed acinar-neuroendocrine carcinoma | Contains both acinar and neuroendocrine cells |
| Mixed acinar-ductal carcinoma | Contains both acinar and ductal cancer cells |
| Acinar cell carcinoma outside the pancreas | Very rarely arises in misplaced pancreatic tissue, for example in the stomach wall |
Pancreatoblastoma, a childhood tumour, also shows acinar differentiation but is a separate disease.
How it differs from common pancreatic cancer
| Feature | Acinar cell carcinoma | Ductal adenocarcinoma |
|---|---|---|
| Cell of origin | Enzyme-producing acinar cells | Duct-lining cells |
| Frequency | Rare | About 9 in 10 pancreatic cancers |
| Size at diagnosis | Often large | Often smaller |
| Appearance on scans | Well-defined, solid, sometimes with dead or bleeding areas | Ill-defined, infiltrating |
| Main gene changes | BRCA1/2, ATM, APC/beta-catenin, BRAF fusions | KRAS, TP53, CDKN2A, SMAD4 |
| KRAS mutation | Uncommon | Present in over 90% |
| Outlook | Better | Poorer |
3. Causes and risk factors
The cause is not known. Unlike ductal adenocarcinoma, there is no strong link with smoking or pancreatitis.
| Factor | Notes |
|---|---|
| Male sex | More cases in men |
| Age | Mostly middle-aged and older adults |
| Inherited BRCA1, BRCA2 or ATM variants | Found in a proportion of patients; genetic counselling may be offered |
| Lynch syndrome | Rare cases with mismatch repair defects |
| Familial adenomatous polyposis | Very rare association through the APC gene |
The tumours have a distinct genetic make-up. KRAS, TP53 and CDKN2A mutations, which drive most pancreatic cancers, are uncommon in acinar cell carcinoma, while defects in DNA repair genes are found more often (Ikezawa et al., 2024).
4. How does it look
On scans
| Feature | Description |
|---|---|
| Shape | Round or oval, usually well defined |
| Size | Often several centimetres |
| Content | Mostly solid; larger tumours may have dead (necrotic), cystic or bleeding areas |
| Capsule | Some have a thin enhancing rim |
| Ducts | The main pancreatic duct is often less widened than in ductal cancer |
| Liver | The liver is the most common site of spread |
Under the microscope
| Feature | Description |
|---|---|
| Cells | Uniform cells with granular cytoplasm and a central nucleolus |
| Pattern | Small gland-like clusters (acini), solid sheets or trabeculae |
| Stroma | Very little supporting fibrous tissue |
| Stains | Positive for trypsin, chymotrypsin and BCL10 |
| Neuroendocrine stains | Usually negative or only focal, unless mixed |
Special stains are essential to confirm the diagnosis, because acinar cell carcinoma can resemble a neuroendocrine tumour or a solid pseudopapillary neoplasm.
On the skin
When lipase is very high, people may develop tender red lumps on the legs caused by fat breakdown under the skin (subcutaneous fat necrosis).
5. Symptoms
Common symptoms
- Abdominal pain, often in the upper abdomen
- Weight loss and reduced appetite
- Nausea, vomiting or feeling full quickly
- Tiredness
- Back pain
Less common symptoms
| Symptom | Cause |
|---|---|
| Jaundice (yellow skin and eyes) | Less common than in ductal cancer, because the tumour tends to push rather than invade the bile duct |
| Tender skin lumps on the legs | Fat necrosis from excess lipase |
| Painful joints | Fat necrosis around joints |
| Diarrhoea or oily stools | Reduced digestion |
| A lump in the abdomen | Large tumour |
The combination of fat necrosis, joint pain and very high lipase is known as lipase hypersecretion syndrome. It usually occurs with liver metastases.
When to seek medical advice
See your doctor if you have persistent upper abdominal or back pain, unexplained weight loss, jaundice or new tender lumps on the legs with joint pain.
6. Diagnosis
| Test | Purpose |
|---|---|
| CT scan with contrast | Shows the tumour, blood vessels and liver |
| MRI | Further detail of the pancreas and liver |
| Endoscopic ultrasound (EUS) | Close-up view; allows a needle biopsy |
| Biopsy with special stains | Confirms acinar cell carcinoma |
| Serum lipase | Raised in about a quarter to over half of patients |
| AFP | Occasionally raised, especially in children |
| CA 19-9 | Often normal, unlike ductal cancer |
| Genetic testing of tumour and blood | Looks for BRCA1/2, ATM, mismatch repair defects and BRAF fusions |
Staging
Acinar cell carcinoma is staged with the same TNM system as other exocrine pancreatic cancers.
| Stage | General meaning |
|---|---|
| Stage I | Confined to the pancreas |
| Stage II | Larger tumour or spread to a few lymph nodes |
| Stage III | Involves major blood vessels or many lymph nodes |
| Stage IV | Spread to distant organs, usually the liver |
About half of patients already have metastases when diagnosed.
7. Treatment
Surgery
Removing the tumour with clear margins gives the best chance of long-term control.
| Operation | Tumour location |
|---|---|
| Pancreaticoduodenectomy (Whipple procedure) | Head of the pancreas |
| Distal pancreatectomy | Body or tail, often with the spleen |
| Total pancreatectomy | Very occasionally, for extensive tumours |
| Liver resection | In selected people with limited liver spread |
Even after a complete operation, the cancer often recurs, so many teams discuss additional chemotherapy, although its benefit has not been proven in trials (Ikezawa et al., 2024).
Chemotherapy
There is no standard regimen designed for acinar cell carcinoma. Doctors borrow treatments used for pancreatic and bowel cancers, which share some genetic features (Calimano-Ramirez et al., 2022).
| Regimen | Notes |
|---|---|
| FOLFIRINOX (5-FU, oxaliplatin, irinotecan) | Often gives good responses; some complete responses reported |
| Gemcitabine-based combinations | Used, but responses are generally lower |
| Capecitabine or 5-FU with oxaliplatin | Bowel-cancer-type regimens |
| Platinum combinations | Especially if BRCA or other DNA repair genes are altered |
Targeted treatment
| Gene change | Possible treatment |
|---|---|
| BRCA1, BRCA2, PALB2 or ATM | Platinum chemotherapy; PARP inhibitors such as olaparib as maintenance |
| BRAF fusions | MEK inhibitors in selected cases or trials |
| Mismatch repair deficiency | Immunotherapy with checkpoint inhibitors |
| Other rare alterations | Clinical trials matched to the tumour |
Because these alterations are frequent, comprehensive genomic profiling is recommended (Al-Hader et al., 2017).
Radiotherapy
Radiotherapy has a limited, unproven role. It may be considered after surgery with involved margins or for symptom control.
Side effects
| Treatment | Possible side effects |
|---|---|
| Pancreatic surgery | Pancreatic leak, delayed stomach emptying, diabetes, poor digestion |
| FOLFIRINOX | Tiredness, diarrhoea, nerve tingling, low blood counts |
| PARP inhibitors | Nausea, tiredness, anaemia |
| Immunotherapy | Rash, inflammation of the bowel, thyroid or liver |
What treatment involves day to day
| Stage | What to expect |
|---|---|
| Before surgery | Scans, blood tests and a fitness assessment; sometimes a stent to relieve jaundice |
| Hospital stay | Usually 7-14 days after a Whipple or distal pancreatectomy |
| Recovery at home | Several weeks of gradually increasing activity; small meals and enzyme capsules |
| Chemotherapy | FOLFIRINOX is usually given every 2 weeks through a pump worn at home for 2 days |
| Tablets | PARP inhibitors are taken by mouth every day, with regular blood counts |
Lipase hypersecretion syndrome explained
In a small number of people, the tumour releases very large amounts of lipase, the enzyme that digests fat. When this enzyme circulates in the blood, it can break down fat in the skin, around joints and sometimes in bone marrow. The result is tender red nodules, most often on the lower legs, together with swollen, painful joints and sometimes fever.
This syndrome is uncommon, but recognising it matters, because it may be the first clue to an underlying acinar cell carcinoma. Treating the cancer, for example with chemotherapy, often improves the skin and joint symptoms.
8. Outlook (prognosis)
Acinar cell carcinoma usually has a better outlook than ductal adenocarcinoma but a poorer one than pancreatic neuroendocrine tumours. Reported median survival ranges widely, from about one and a half to four years across studies (Al-Hader et al., 2017).
| Factor | Effect |
|---|---|
| Complete surgical removal | Best chance of long survival |
| Spread to the liver at diagnosis | Poorer outlook |
| Response to chemotherapy | Good responses can give years of control |
| DNA repair gene defects | May predict better responses to platinum and PARP inhibitors |
| Young age | Children often do better than adults |
9. Follow-up
| Follow-up | Purpose |
|---|---|
| CT scans every 3-6 months for the first years | Look for recurrence, especially in the liver |
| Lipase or AFP | Useful if raised at diagnosis |
| Diabetes checks | After pancreatic surgery |
| Nutrition review | Enzyme capsules and weight monitoring |
| Genetic counselling | If an inherited variant is found |
10. Living with acinar cell carcinoma
- Take pancreatic enzyme capsules with meals and snacks if prescribed
- Eat small, frequent meals if you feel full quickly
- Monitor blood sugar if you have diabetes after surgery
- Report fever, jaundice or worsening pain promptly
- Ask about genetic testing and what it means for your family
- Keep active within your limits to maintain strength
- Seek support from pancreatic cancer charities
11. Frequently asked questions
| Question | Answer |
|---|---|
| Is it the same as ordinary pancreatic cancer? | No; it starts in different cells and behaves differently |
| Is the outlook better? | Generally yes, especially after complete surgery |
| Why do I need genetic testing? | Many tumours have changes that open up targeted treatments |
| Can children get it? | Yes, rarely; outcomes are often better in children |
| Why does my skin hurt in lumps? | High lipase can break down fat under the skin |
| Will I need chemotherapy after surgery? | Sometimes; its benefit is uncertain and is discussed case by case |
| Can it come back after surgery? | Yes, recurrence is common, so regular scans are important |
| Is it linked to smoking or alcohol? | No clear link has been shown, unlike ductal pancreatic cancer |
12. Questions to ask your care team
- Has the diagnosis been confirmed with special stains?
- Can the tumour be removed surgically?
- Has my tumour had genomic profiling?
- Should I have germline (blood) genetic testing?
- Which chemotherapy do you recommend, and why?
- Am I eligible for any clinical trials?
- How often will I have scans?
Resources
- Al-Hader, A. et al. (2017) ‘Pancreatic acinar cell carcinoma: a review on molecular profiling of patient tumors’, World Journal of Gastroenterology, 23(45), pp. 7945-7951.
- Calimano-Ramirez, L.F. et al. (2022) ‘Pancreatic acinar cell carcinoma: a comprehensive review’, World Journal of Gastroenterology, 28(40), pp. 5827-5844.
- Chaudhary, P. (2015) ‘Acinar cell carcinoma of the pancreas: a literature review and update’, Indian Journal of Surgery, 77(3), pp. 226-231.
- Ikezawa, K. et al. (2024) ‘Comprehensive review of pancreatic acinar cell carcinoma: epidemiology, diagnosis, molecular features and treatment’, Japanese Journal of Clinical Oncology, 54(3), pp. 271-281.
- National Cancer Institute (2026) Pancreatic Cancer Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/pancreatic/hp/pancreatic-treatment-pdq (Accessed: October 2026).
Prepared by the editorial team, October 2026.